SCHEMBL3565845

SCHEMBL3565845

Oc1ccc(-c2oc3nccc(Cl)c3c2-c2ccccc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 7/20 0.49
TNK2 Q07912 3/20 0.48
CHEK1 O14757 3/20 0.43
MAP2K1 Q02750 1/20 0.43
KDR P35968 3/20 0.43
LCK P06239 2/20 0.43
JAK3 P52333 2/20 0.43
ALDH1A1 P00352 4/20 0.43
HPGD P15428 4/20 0.43
KDM4E B2RXH2 2/20 0.43
UBE2N P61088 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD17B10 Q99714 2/20 0.41
TSHR P16473 1/20 0.41
EGFR P00533 2/20 0.40
MAPT P10636 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CCNE2 O96020 1/20 0.40
CDK1 P06493 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13436251 0.92 TNK2 (0.55) AURKATNK2CHEK1MAP2K1KDR
SCHEMBL3051089 0.83 TNK2 (0.45) AURKATNK2CHEK1MAP2K1KDR
SCHEMBL6748429 0.83 KDM4E (0.63) TNK2CHEK1KDRALDH1A1HPGD
SCHEMBL2977130 0.81 TNK2 (0.58) AURKATNK2CHEK1MAP2K1ALDH1A1
SCHEMBL3569303 0.76 TNK2 (0.37) AURKATNK2CHEK1MAP2K1KDR
SCHEMBL3630335 0.75 ALDH1A1 (0.45) AURKATNK2KDRLCKJAK3
SCHEMBL14923117 0.75 AURKA (0.48) AURKATNK2CHEK1MAP2K1ALDH1A1
SCHEMBL3566807 0.74 TNK2 (0.63) AURKATNK2CHEK1MAP2K1KDR
SCHEMBL13436256 0.74 TNK2 (0.67) TNK2KDRLCKJAK3EGFR
SCHEMBL3572697 0.73 TNK2 (0.68) AURKATNK2KDRLCKJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US disclosed
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US disclosed
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US disclosed
EP-1791845-A2 FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS AMGEN INC. (US) 2007-06-06 EP disclosed
WO-2006130160-A2 FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS AMGEN INC. (US) 2006-12-07 WO disclosed
US-20060046977-A1 Furanopyridine derivatives and methods of use AMGEN INC. 2006-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060046977-A1 Furanopyridine derivatives and methods of use LCK, NFATC1, MINK1 AURKA 130/4885TNK2 22/4885CHEK1 209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.